Primary Peritoneal Cancer Clinical Trials in Chicago, Illinois

3 studies are recruiting for primary peritoneal cancer in Chicago, Illinois right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

   This study is researching an experimental drug called ubamatamab, also referred to as "study drug". The study is focused on participants who have advanced ovarian cancer. The aim of the study is to see how safe, tolerable, and effective the study drug is on its own and in combination with other ant…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Chicago, Chicago, Illinois

   Locations

   56 in total

   Run by

   Regeneron Pharmaceuticals

   See if you can join NCT06787612 on ClinicalTrials.gov

2. A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

   Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of neoadjuvant carboplatin and mirvetuximab soravtansine in participants with folate receptor alpha (FRα) -expressing advanced-stage serous …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Rush Md Anderson Cancer Center /ID# 274926, Chicago, Illinois

   Locations

   70 in total

   Run by

   AbbVie

   See if you can join NCT06890338 on ClinicalTrials.gov

3. A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

   This study is researching an investigational drug called REGN5668 : * alone or, * combined with cemiplimab (also known as REGN2810) or, * combined with both cemiplimab and fianlimab (also known as REGN3767), or * combined with ubamatamab (also known as REGN4018), with or without sarilumab. The main…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois

   Locations

   28 in total

   Run by

   Regeneron Pharmaceuticals

   See if you can join NCT04590326 on ClinicalTrials.gov